BCL2 and neoplasm: To investigate whether the expression of AGK could be a biomarker for predicting the response to venetoclax in DLBCL patients, we performed H&E and BCL-2 immunohistochemical staining for human DLBCL primary tumor tissues of 33 individual patients.